Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Investinthefuture,
You sir are correct. I am sure half the calls I received last week were not just the warrant guys but were also guys who shorted their shares.
I am usually pretty good at this but I totally misread reading the tea leaves this time hahaha.
If I had read through it, I would have sold myself – that’s the market though.
Either way, I have been and continue to be a long term holder.
Long and strong.
El Guapo Roboto,
El Guapo Very simple – DEMAND
As I mentioned in previous posts they originally wanted $25 to $35 million and only received $13 million.
Now lets assume this is a HOT issue and they raise $20 million more over-night. Then they would have $33 million plus all athe warrants that were exercised.
They will then be well financed right through total commercialization and will have no need to come to market again – at least for a few years.
Keep in mind, this is at $2 plus versus $1.40 so we all knew they wanted $25 to $35 million and now are raising funds at a higher range.
Positive in my opinion.
Long and Strong
I believe the deal will be done around $2.10 to $2.20.
I also believe that only a phase of tissue testing will be done and the balance in the second half of the year. Just my opinion.
El Guapo Roboto,
Brooks is useless. Provides nothing of substance in responses. Just the usual standard BS. She is essentially a glorified secretary and can maybe assist you in getting a call now and then.
The bankers probably had demand from investors and dangled the funds in front of Titan who would not resist. Remember they wanted something like $25 million to $30 million and only raised $13 million last time. Therefore this is not such bad news as you think as they are raising here over $2.00 versus having done the whole raise last time at $1.40.
Glass is half full and now they will get all cashed up.
Long and strong.
Yes, a halt is on all platforms.
CUIN2
It had nothing to do with Raymond James at all or they would have been in the deal.
This is most likely demand for the stock from institutions let by the last deal. That is why you see Dundee and Bayfront mentioned in the news release.
Also in the last financing they wanted about $20 million and only got $13 million and they are not waiting for the warrants to be exercised. They want a full coffer of money to finish the product and go to commercialization.
Its unfortunate the company did not put out news to drive the share price higher and do a higher priced financing but as you have seen in previous posts I have been critical of their poor IR. They don’t put out enough information and their IR person is weak. What are we to do???
Anyway, I am bullish on this assuming they just took advantage of the recent strength in the share price to fill the tank up to full.
To the US investors who wanted in, get in NOW as I suspect the next financing will be in 2 years (if they are still around and not taken out) to set up their plant or distribution…….
Long and strong.
Here is most likely what will happen:
Financing will be in the same context as last financing. Last one was around a discount of 18% to 19% so I suspect the same here.
If that is the case then the price will be around $2.10 for the unit. This is my best guess.
This is going to be great for Titan as it will bring in the balance of the funds to bring them to commercialization.
For all those not in the stock yet or for those wanting more shares, I suspect it will drop to around the financing price (my guess above based on conventional logic) allowing investors to buy in cheap for the last time!!!!!
As usual, long and strong.
Stockwatch News
To Stockwatch News
Today at 3:30 PM
Titan Medical arranges overnight marketed offering
Ticker Symbol: C:TMD
Titan Medical arranges overnight marketed offering
Titan Medical Inc (C:TMD)
Shares Issued 84,530,305
Last Close 4/4/2014 $2.36
Monday April 07 2014 - News Release
Mr. John Hargrove reports
TITAN MEDICAL INC. ANNOUNCES PUBLIC FINANCING
Titan Medical Inc. has entered into an agreement with Dundee Securities Ltd., under which the agent has agreed to offer for sale on an overnight marketed best-efforts basis, units of the company, each unit consisting of one common share and one common share purchase warrant, details of which will be determined in the context of the market. In connection with the offering, BayFront Capital Partners Ltd. has been appointed as a selling group member.
The offering is scheduled to close on or about April 23, 2014. The offering is subject to a number of conditions, including, without limitation, receipt of all regulatory approvals. The units will be qualified for sale by way of a prospectus supplement (to the company's short-form base-shelf prospectus dated Oct. 15, 2012), which will be filed in the provinces of British Columbia, Alberta and Ontario.
In connection with the offering, the agent will receive a cash commission equal to 6 per cent of the gross proceeds raised under the offering and that number of non-transferable broker warrants equal to 6 per cent of the number of units sold. Each broker warrant will be exercisable into one unit of the company for a period of 24 months from the closing of the offering at a price equal to the offering price.
The net proceeds of the offering will be used for continuing development and commercialization of robotic surgery technologies, and general working capital requirements.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd.
HALT –
Stockwatch News
To Stockwatch News
Today at 3:22 PM
Titan Medical halted at 12:20 p.m. PT
Ticker Symbol: C:TMD
Titan Medical halted at 12:20 p.m. PT
Titan Medical Inc (C:TMD)
Shares Issued 84,530,305
Last Close 4/4/2014 $2.36
Monday April 07 2014 - Halt Trading
Titan Medical Inc. has been halted at 12:20 p.m. PT on April 7, 2014, at the request of the company, pending news.
© 2014 Canjex Publishing Ltd.
Good Morning Everyone,
CUIN2,
This is perfect. That is what many of us have been saying all along.
We compared what happened to Mako.....and although some on this board believe TMD will go it alone, I don't think that will ever happen. Titan would be a great compliment for Mako on the soft tissue side or any of the other big boys who want in on robotics.
I strongly feel that within a year and once Titan releases the complete results of their tissue testing (compete results might be some time in the second half of the year - not just the initial results we are all waiting for sometime between now and the release of Q1 as someone suggested on the board earlier) are released Titan will start to see the real offers.
If you were J&J you would wait to see the results of that very important piece of the puzzle and then make a decision to buy or not. It's better to pay a bit more once the risk is reduced.
The problem is that Titan is too silent. They need to help their stock price too so when the offer comes in, they are starting from a higher base. We all know Titan is worth more than $5.00 however that all they would get today. They need to feed the market some information so we see $5.00 today and can get taken out at a $10 price range.
On another note, I received a call from another group who could use a lend on shares to the tune of over 1 million shares. This is warrants related. Stay tuned for the financials or MD&A so we see how many warrants really get exercised.
Summary to my last point, that explains the pressure of over 1 million shares being sold keeping the price down. Titan could pop on even the smallest amount of news.
HC,
I am not sure if it's a momentum thing that ISRG has lost as the Nasdaq was down a lot on Friday. Keep in mind, it had one hell of a run this past week.B you are bound to see profit taking.
I do however agree with the rest of your math though.
There is no question that the place to be is in Titan. You get much more leverage and upside as well as a company that can move very quickly and easily.
Their IR sucks but what can ya do.
Impressive day today in the face of what the markets over-all are doing.
I think Titans performance is great - especially given that I received another call to borrow my shares.
Go Titan!!!!
Come on management - give us some news.
That National Bank seller finally got off 32,600 shares.
He is now sitting at $2.34 offering 20,000 shares.
Behind that RBC is offering 52,000 at $2.35
I prefer the type of sellers like what BMO just did. They wanted off about 10,000 shares and just put the order in - wham they are filled and out of the way.
I have a strong suspicion that we will find out that another 1 million or more warrants have been exercised.
Good morning Everyone,
The short report is out and the shorts actually increased a bit by 52,617 to 2,252,907 as of March 31.
Again, I think from my intel that about 500,000 of this is covered shorts through the exercise of warrants but still a decent number that has to cover at some time.
Just an ounce of decent news with an update and they will get burned.
Have a great day.
Be long and strong.
Secrets of sports superstars use the healing power of light
THERALASE – Canadian company’s laser innovations helps your body heal itself while shedding light on new treatments for cancer.
“Our lasers penetrate further, heal faster and relieve your suffering; sometimes after only minutes of treatment…The technology effectively treats pain and heals wounds without the side effects of drugs” - Roger Dumoulin-White, President and CEO of Theralase.
What do baseball great Roy Halladay, hockey legend Bobby Orr, wrestling superstar Hulk Hogan and four time track and field Olympian Johnny Gray have in common? Yes there was pain, anguish, fatigue and injuries that littered their road to success.
But there is another thing that helped them triumph over their adversities.
It is the healing power of light developed by Ontario-based Theralase Technologies Inc., (TSX VENTURE: TLT) (OTCBB: TLTFF) whose inspirational innovations have been hailed by the global medical fraternity and showcased by the likes of Popular Mechanics.
The testimony of the sports superstars speak for themselves; “I use the Theralase laser to keep my throwing arm healthy. It reduces fatigue and allows me to play at my peak game after game after game,” writes Halladay, 36, the two time Cy Young Award winner who recently retired after 16 seasons in the majors.
Orr, undoubtedly one of hockey’s greatest players ended his career early after sustaining 13 left knee surgeries, leaving him unable to walk without severe pain or perform any stressful physical activity. After Orr received 16 Theralase laser treatments to his left knee, his pain quickly diminished and he returned to daily physical activity.
Hogan had such debilitating knee pain that he could barely enter the ring without limping. He was able to compete professionally again, after a dozen Theralase laser treatments.
“Not having the Theralase therapeutic medical laser system for treatment is like Superman forgetting to put on his cape,” opined Johnny Gray, a four time American 800 meter Olympian, who won the bronze medal at the Barcelona Olympics of 1992.
From sports superstars to patients suffering from chronic pain, neural muscular-skeletal conditions and wound healing, technology from Theralase has been helping millions of people to recover with a safe, effective and painless therapy that uses the body’s own natural healing processes.
Theralase lasers work by supplying energy to the body in the form of billions of photons of light. The body absorbs this laser light on a cellular level and transforms it into chemical energy, which the body then uses to commence its own tissue repairs.
“The biostimulating effect of our laser therapy causes an elimination of pain, decrease in inflammation and an increase in tissue regeneration and healing,” said Roger Dumoulin-White, President and CEO of Theralase. “Our lasers help you regain the active and healthy lifestyle you yearn for by utilizing the power of light energy,” said Dumoulin-White whose research team’s innovations are backed by over 3,000 clinical studies worldwide that have proven the success of therapeutic lasers in the healing of neural muscular-skeletal conditions.
“Our lasers penetrate further, heal faster and relieve your suffering; sometimes after only minutes of treatment…The technology effectively treats pain and heals wounds without the side effects of drugs”
Founded in 1995, Theralase designs, develops, manufactures and markets patented, superpulsed laser technology which penetrates four inches below the skin while other laser treatments only go half an inch deep. Treatable conditions that the Theralase has been proven effective on include: low back, knee, neck and hip pain, all the way to tendinitis, whiplash, diabetic ulcers and psoriasis. It can also be used for sinusitis, cold sores and, when applied to specific acupuncture points, smoking cessation, weight loss and addiction, said Dumoulin-White.
Currently there are more than 1200 Theralase laser machines in use throughout North America and worldwide, including places as far away as the Philippines, Malaysia and India.
Theralase laser treatments are now widely in use in the horse racing industry and in veterinarian practices to help animals recover quicker by eliminating their pain and healing their injuries. The Theralase technology is endorsed in the professional sports circuit by such notables as the: Toronto Blue Jays, Toronto Raptors, Toronto FC, Washington Wizards, Jacksonville Jaguars, Carolina Panthers and Montreal Canadians.
Another facet of the Company, involves using laser light to activate Photo Dynamic Compounds (PDCs) to specifically target and destroy bacteria, viruses, as well as microbial pathogens, such as bacteria, associated with food contamination.
It is this field that Dumoulin-White is confident that Theralase will leave the pack involved in cold laser technology behind.
In October 2004, researchers at Virginia Polytechnic Institute and State University working with a team from Theralase announced they had developed molecular compounds, known as PDCs, that when activated by laser light, had the ability to destroy cancer cells without the harmful side effects of chemotherapy, radiation or a surgeon’s scalpel.
The group’s “molecular machine” when combined with deep-penetrating laser technology from Theralase, could help combat fast-growing cancers, such as: breast, prostate, and lung, which up until now had not been able to be penetrated by light therapies.
The development of this technology has now progressed to a two to five year road map for Food and Drug Administration approval.
In the spring of 2012, Theralase announced that its anti-cancer PDC technology was found to completely destroy subcutaneous (under the skin) colon cancer tumors in a mouse model.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase said, “In cancer treatment, destroying the tumor is half the battle, while the other half is preventing the cancer from recurring. These findings are important because they demonstrate that our leading drug candidate, in combination with a specific dose of light, can prevent the cancer from returning. Preventing cancer from recurring in animal models is an important benchmark in developing new cancer therapeutics aimed at prolonging life.”
“Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future,” said Dumoulin-White.
But it’s the possibilities in the future that excite the innovators and investors in Theralase the most.
An enhanced therapeutic laser system with built-in biofeedback sensors that will be able to monitor the amount of laser light delivered to tissue is in the works providing a technology that will deliver patient specific treatments effectively eliminating pain and breaking the pain cycle for a $100 Billion a year problem in the US healthcare market.
In the war against cancer, the PDC technology of Theralase raises the possibility of eliminating a life altering disease in an afternoon without pain or serious discomfort, something that has only been dreamed about by the medical community for centuries.
“We are working with our researchers and investors to make the seemingly impossible, possible,” added Dumoulin-White.
Why invest in Theralase
From an investment point of view, analysts look at Theralase as being under the radar of major pharmaceutical corporations but agree that the “lid is coming off this story quickly”.
Theralase (TSX VENTURE: TLT) (OTCBB: TLTFF) has two main divisions. The first division is the Therapeutic Laser Technology (TLT) Division which is focused on designing, manufacturing and distributing cutting-edge therapeutic laser technology to eliminate pain in patients suffering from acute and chronic pain.
Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain annually states a newly released market analysis. In many cases, 50% of the people taking medicines or who have opted for surgery are not satisfied with the results and are still in significant daily pain.
The pain industry in the United States alone is estimated to be worth $100 billion annually.
Theralase’s second division, the Photo Dynamic Therapy (PDT) Division is researching and developing the next cure for cancer. These Photo Dynamic Compounds (PDCs) have the ability to localize into cancer cells and when light activated, destroy the cancer cell through a natural cell death process called apoptosis. If successful, this technology could revolutionize the cancer industry by becoming a first line therapy and displacing the standard procedures of care, such as: surgery, radiation therapy and chemotherapy, which all affect quality of life and have serious side effects.
Key Theralase Highlights:
PDT Division:
Developing a therapeutic compound for the $3.9 billion bladder cancer market
Platform technology for development of additional cancer therapeutics
Favourable preclinical data (in-vitro and in-vivo) in bladder and breast cancer cell lines
Partnership validation: Ontario Cancer Institute, Princess Margaret Hospital; University Health Network
Proprietary technology with strong IP portfolio: patented PDC cancer destruction, multiple issued patents
TLT Division:
Proven ability to develop and commercialize technologies: TLC-1000 cold laser technology for non-invasive pain management currently generates $1.5 to 2 million of revenue annually with over 1200 practitioners now using the technology to heal their patients daily.
Second generation (TLC-2000) launch in 4Q2014, along with a new recurring revenue business model
Proprietary technology with strong IP portfolio: patented biofeedback technology, multiple issued patents
Strong financials: No debt, positive cash flow / double digit growth
Only technology proven to eliminate pain, reduce inflammation and accelerate tissue healing through 3 independent cellular pathways.
Cleared by FDA, Health Canada and CE for sale in 180 countries
Large installed base of over 800 systems sold in Canada and 400 systems in the US and internationally
Theralase currently generates $1.5 to 2 million in annual revenue from the laser therapy division of the company, and has a strategy in place to increase that figure by 300-400% in 2014. The growth strategy includes expansion across Canada and aggressively into major U.S. markets, as well as introducing a recurring revenue model with the release of the TLC-2000.
Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Market One Media Group makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Market One Media Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article. Therefore, in no case whatsoever will Market One Media Group Inc. be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or editorial or for any related damages.
Secrets of sports superstars use the healing power of light
THERALASE – Canadian company’s laser innovations helps your body heal itself while shedding light on new treatments for cancer.
“Our lasers penetrate further, heal faster and relieve your suffering; sometimes after only minutes of treatment…The technology effectively treats pain and heals wounds without the side effects of drugs” - Roger Dumoulin-White, President and CEO of Theralase.
What do baseball great Roy Halladay, hockey legend Bobby Orr, wrestling superstar Hulk Hogan and four time track and field Olympian Johnny Gray have in common? Yes there was pain, anguish, fatigue and injuries that littered their road to success.
But there is another thing that helped them triumph over their adversities.
It is the healing power of light developed by Ontario-based Theralase Technologies Inc., (TSX VENTURE: TLT) (OTCBB: TLTFF) whose inspirational innovations have been hailed by the global medical fraternity and showcased by the likes of Popular Mechanics.
HandoutHandoutHandoutHandoutHandoutHandoutHandoutHandoutroger-headshot-jul09_REVHandout
Handout
RightLeft
1 2 3 4 5 6 7 8 9 10
The testimony of the sports superstars speak for themselves; “I use the Theralase laser to keep my throwing arm healthy. It reduces fatigue and allows me to play at my peak game after game after game,” writes Halladay, 36, the two time Cy Young Award winner who recently retired after 16 seasons in the majors.
Orr, undoubtedly one of hockey’s greatest players ended his career early after sustaining 13 left knee surgeries, leaving him unable to walk without severe pain or perform any stressful physical activity. After Orr received 16 Theralase laser treatments to his left knee, his pain quickly diminished and he returned to daily physical activity.
Hogan had such debilitating knee pain that he could barely enter the ring without limping. He was able to compete professionally again, after a dozen Theralase laser treatments.
“Not having the Theralase therapeutic medical laser system for treatment is like Superman forgetting to put on his cape,” opined Johnny Gray, a four time American 800 meter Olympian, who won the bronze medal at the Barcelona Olympics of 1992.
From sports superstars to patients suffering from chronic pain, neural muscular-skeletal conditions and wound healing, technology from Theralase has been helping millions of people to recover with a safe, effective and painless therapy that uses the body’s own natural healing processes.
Theralase lasers work by supplying energy to the body in the form of billions of photons of light. The body absorbs this laser light on a cellular level and transforms it into chemical energy, which the body then uses to commence its own tissue repairs.
“The biostimulating effect of our laser therapy causes an elimination of pain, decrease in inflammation and an increase in tissue regeneration and healing,” said Roger Dumoulin-White, President and CEO of Theralase. “Our lasers help you regain the active and healthy lifestyle you yearn for by utilizing the power of light energy,” said Dumoulin-White whose research team’s innovations are backed by over 3,000 clinical studies worldwide that have proven the success of therapeutic lasers in the healing of neural muscular-skeletal conditions.
“Our lasers penetrate further, heal faster and relieve your suffering; sometimes after only minutes of treatment…The technology effectively treats pain and heals wounds without the side effects of drugs”
Founded in 1995, Theralase designs, develops, manufactures and markets patented, superpulsed laser technology which penetrates four inches below the skin while other laser treatments only go half an inch deep. Treatable conditions that the Theralase has been proven effective on include: low back, knee, neck and hip pain, all the way to tendinitis, whiplash, diabetic ulcers and psoriasis. It can also be used for sinusitis, cold sores and, when applied to specific acupuncture points, smoking cessation, weight loss and addiction, said Dumoulin-White.
Currently there are more than 1200 Theralase laser machines in use throughout North America and worldwide, including places as far away as the Philippines, Malaysia and India.
Theralase laser treatments are now widely in use in the horse racing industry and in veterinarian practices to help animals recover quicker by eliminating their pain and healing their injuries. The Theralase technology is endorsed in the professional sports circuit by such notables as the: Toronto Blue Jays, Toronto Raptors, Toronto FC, Washington Wizards, Jacksonville Jaguars, Carolina Panthers and Montreal Canadians.
Another facet of the Company, involves using laser light to activate Photo Dynamic Compounds (PDCs) to specifically target and destroy bacteria, viruses, as well as microbial pathogens, such as bacteria, associated with food contamination.
It is this field that Dumoulin-White is confident that Theralase will leave the pack involved in cold laser technology behind.
In October 2004, researchers at Virginia Polytechnic Institute and State University working with a team from Theralase announced they had developed molecular compounds, known as PDCs, that when activated by laser light, had the ability to destroy cancer cells without the harmful side effects of chemotherapy, radiation or a surgeon’s scalpel.
The group’s “molecular machine” when combined with deep-penetrating laser technology from Theralase, could help combat fast-growing cancers, such as: breast, prostate, and lung, which up until now had not been able to be penetrated by light therapies.
The development of this technology has now progressed to a two to five year road map for Food and Drug Administration approval.
In the spring of 2012, Theralase announced that its anti-cancer PDC technology was found to completely destroy subcutaneous (under the skin) colon cancer tumors in a mouse model.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase said, “In cancer treatment, destroying the tumor is half the battle, while the other half is preventing the cancer from recurring. These findings are important because they demonstrate that our leading drug candidate, in combination with a specific dose of light, can prevent the cancer from returning. Preventing cancer from recurring in animal models is an important benchmark in developing new cancer therapeutics aimed at prolonging life.”
“Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future,” said Dumoulin-White.
But it’s the possibilities in the future that excite the innovators and investors in Theralase the most.
An enhanced therapeutic laser system with built-in biofeedback sensors that will be able to monitor the amount of laser light delivered to tissue is in the works providing a technology that will deliver patient specific treatments effectively eliminating pain and breaking the pain cycle for a $100 Billion a year problem in the US healthcare market.
In the war against cancer, the PDC technology of Theralase raises the possibility of eliminating a life altering disease in an afternoon without pain or serious discomfort, something that has only been dreamed about by the medical community for centuries.
“We are working with our researchers and investors to make the seemingly impossible, possible,” added Dumoulin-White.
Why invest in Theralase
From an investment point of view, analysts look at Theralase as being under the radar of major pharmaceutical corporations but agree that the “lid is coming off this story quickly”.
Theralase (TSX VENTURE: TLT) (OTCBB: TLTFF) has two main divisions. The first division is the Therapeutic Laser Technology (TLT) Division which is focused on designing, manufacturing and distributing cutting-edge therapeutic laser technology to eliminate pain in patients suffering from acute and chronic pain.
Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain annually states a newly released market analysis. In many cases, 50% of the people taking medicines or who have opted for surgery are not satisfied with the results and are still in significant daily pain.
The pain industry in the United States alone is estimated to be worth $100 billion annually.
Theralase’s second division, the Photo Dynamic Therapy (PDT) Division is researching and developing the next cure for cancer. These Photo Dynamic Compounds (PDCs) have the ability to localize into cancer cells and when light activated, destroy the cancer cell through a natural cell death process called apoptosis. If successful, this technology could revolutionize the cancer industry by becoming a first line therapy and displacing the standard procedures of care, such as: surgery, radiation therapy and chemotherapy, which all affect quality of life and have serious side effects.
Key Theralase Highlights:
PDT Division:
Developing a therapeutic compound for the $3.9 billion bladder cancer market
Platform technology for development of additional cancer therapeutics
Favourable preclinical data (in-vitro and in-vivo) in bladder and breast cancer cell lines
Partnership validation: Ontario Cancer Institute, Princess Margaret Hospital; University Health Network
Proprietary technology with strong IP portfolio: patented PDC cancer destruction, multiple issued patents
TLT Division:
Proven ability to develop and commercialize technologies: TLC-1000 cold laser technology for non-invasive pain management currently generates $1.5 to 2 million of revenue annually with over 1200 practitioners now using the technology to heal their patients daily.
Second generation (TLC-2000) launch in 4Q2014, along with a new recurring revenue business model
Proprietary technology with strong IP portfolio: patented biofeedback technology, multiple issued patents
Strong financials: No debt, positive cash flow / double digit growth
Only technology proven to eliminate pain, reduce inflammation and accelerate tissue healing through 3 independent cellular pathways.
Cleared by FDA, Health Canada and CE for sale in 180 countries
Large installed base of over 800 systems sold in Canada and 400 systems in the US and internationally
Theralase currently generates $1.5 to 2 million in annual revenue from the laser therapy division of the company, and has a strategy in place to increase that figure by 300-400% in 2014. The growth strategy includes expansion across Canada and aggressively into major U.S. markets, as well as introducing a recurring revenue model with the release of the TLC-2000.
Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Market One Media Group makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Market One Media Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article. Therefore, in no case whatsoever will Market One Media Group Inc. be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or editorial or for any related damages.
And there you have it folks.
Scotia just put in market order for 100,000 shares and knocked us down.
As per my usual comments, this is great as it was all absorbed and only took it down a few cents from its daily high.
This stock is showing a tremendous amount of strength and resilience
I cannot believe I am saying this but I am thinking of actually stepping in for more shares as that was a great sign.
This is great news. There are for sure more people shorting here to exercise more warrants.
I just received a call from someone to lend my shares to someone so they could short their shares and exercise their warrants and not get bought in.
More money for Titan and stronger hands are buying shares!!!!!!
A small piece of news with some type of update and we could see a nice run.
As usual, long and strong.
Oh look. National Bank is back offering their 51,000 at $2.35
As usual, they will most likely pull it once they get close LOL
What a joke the trading on Titan can be.
Again National Bank was showing 50,000 shares for sale at $2.25 and now suddenly they pull their order.
Anyway its also nice to see that BMO and their small downtick orders have disappeared today as well.
Theralase, Acadia sign research deal
Ticker Symbol: C:TLT
Theralase, Acadia sign research deal
Theralase Technologies Inc (C:TLT)
Shares Issued 66,530,642
Last Close 4/2/2014 $0.375
Thursday April 03 2014 - News Release
Mr. Roger Dumoulin-White reports
THERALASE ADVANCES ANTI-CANCER TECHNOLOGY PLATFORM
Theralase Technologies Inc. has advanced its anti-cancer technology platform through an executed research agreement with Acadia University. Under the terms of the agreement, Acadia will supply initial quantities of Theralase's lead Photo Dynamic Compounds (PDCs) and the Standard Operating Procedures (SOPs) of how to synthesize them.
The lead PDCs will be used by Theralase to commence toxicity analysis and manufacturing ramp up via Contract Manufacturing Organization (CMO); both mandatory prerequisites in the evolution towards an approved Investigational New Drug (IND) application from the FDA and Health Canada. With larger quantities of the PDCs in hand and an approved IND; Theralase would be in the position to commence a Phase 1/2a human clinical trial for the lead indication of bladder cancer, as early as 1Q2015.The lead PDCs have advanced towards international patent protection under a filed Patent Cooperation Treaty (PCT) application. Once approved at this phase, the Company plans to provide wide spread patent coverage of the PDCs across numerous countries during the national phase.Dr. Sherri McFarland, Professor of Chemistry at Acadia University, the originator of the PDCs under worldwide exclusive licence to Theralase stated, "I am truly excited to work with Theralase in the development of these PDCs and be associated with their lead scientists and clinical oncologists to develop the next generation of anti-cancer technology. From the raw research I have observed, this technology has the potential to not only destroy one type of cancer, but many. I am convinced that this technology has the opportunity to go mainstream as a primary treatment in the destruction of cancer, within the next few years."Dr. David MacKinnon, Dean, Research and Graduate Studies at Acadia University stated, "We are pleased to have partnered with Theralase in the development of these PDCs for the destruction of cancer. It is rewarding to advance research originally developed in our chemistry labs from conception through to commercialization knowing that it may one day be a cure for cancer."Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated that, "Sherri's strong background as a medicinal chemist and specialist in photochemistry, coupled with my scientific and medical knowledge as to how laser light interacts at the molecular and cellular level, will bring a new platform of cutting-edge anti-cancer technologies to the forefront within the next few years."Roger Dumoulin-White, President and CEO of Theralase stated that, "I am delighted that Acadia has partnered with Theralase in the commercialization of technology that may provide a new front line treatment for cancer in the not too distant future. With good partners, disruptive technologies are born, which can make marked impacts on devastating diseases such as cancer, in our lifetime. I am humbled to be part of the process."
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd.
Again, another one I am in agreement with.
Management is doing a great job with the company however they are complete rookies when it comes to IR. Their IR person is just as bad. She might be friendly and can take a message and have someone call you back but that is all.
Titan has done nothing to help themselves and or their share price at all which is totally unfortunate for all of the shareholders.
Imagine if they put out some simple information and updates on their progress – we could be at $4.00 or $5.00 right away. This would be amazing so if a real takeover offer came along you could apply that method of valuation and Titan could be taken out at substantially higher prices like $9.00 or $10.00
Management needs to step up a bit and help the share price as well.
Either way, I am still long.
Then we both agree with one another.
My opinion is the logical candidate “SHOULD” be ISRG. They could take out Titan now for all cash or all stock at a double to Titans current share price and it would not make a dent in in their pocket or float.
However ISRG will probably not be the takeout. It will most likely be and J&J, Stryker…….you are correct.
Tony Pullen has been around for a long time and has seen lots go on in this space. He really knows it well – a healthcare veteran.
He is dead on in my opinion. Titan is going to get taken out, by who no one knows yet however the logical candidate will be ISRG.
They get a company with all the patents and real short term to go to the market. Most importantly a superior product to what they have now with all TMD’s bells and whistles.
Good Morning and Welcome to the board.
You are correct that this board appears to be a high quality board with quality information on both the medical side as well as the investment side.
There is no useless pumping as can be found on many other boards.
Thanks very much for your Maiden Post and I hope not your last one.
Keep the good info and intel coming. You will find this board receptive and on occasion challenging information if its questionable – however all for a good cause.
I had a price target around $5 but I do like yours much better LOL.
Another nice day of trading today.
Too bad a crappy sub-par firm like Jennings comes in around the last 20 minutes or so of trading to sell.
They put up a bunch of shares and hit the market, then they were offering 9,000 shares at $2.21, that lasted 2 minutes before dropping it to $2.20 and then to $2.19…..you get the picture.
All at the same time BMO continues to come in with their market order for 100 to 900 shares at a time also down-ticking the price down. Its comical to watch.
Anyway, it was a great day turning over the number of shares we did today. Well over 700,000 in Canada alone.
Just when I thought it had seen it all, someone comes in takes out the Jennings order which was an iceberg so others came in to sell behind it and not get caught waiting for the iceberg to get filled first – again comes along BMO for a downtick and sale on 200 shares and then with one minute to go along comes TD with an order to sell at $2.18.
This is funny.
"la cerveza por favor" where the sun is hot and with beautiful beaches, lol
Wow. What terrific volume.
I have heard that there is about 500,000 shares shorted that are uncovered right now. This is probably part of the 2.2 million reported as of the 15th of March.
This means one of two things or a mixture of both:
Firstly, there is simple naked shorting going. This will be good as they have to cover some time unless the shorters have virtual unlimited funds and continue to short.
Secondly, much of the shorting is actually covered shorts through the warrants. This means that people have been shorting the shares and exercising their warrants to cover the short position. This is my understanding of what most if not all of the 500,000 shorts I referred to above are.
So how does this affect us longs? Well it does not really affect us other than we now have a clear understanding of where much of the selling is coming from. This is positive as more shares are hitting the market and frankly getting eaten up very cheaply in my opinion (I think we all agree this stock should be at least $5) but it also means that the company is receiving the funds into their treasury.
In summary, this is very positive.
We will have to wait a quarter or two to compare the proper increase in the share float now as well but I am certain that post the recent financing you will see an increase in the shares outstanding somewhere in the range of 500,000 to 1 million shares.
All the best and stay long as this is going higher
English - The Language of Global Business?
Korean - ESL / EFL Job Services
English speaking is big business, Korea can be a culture shock for anyone coming over for the first time. Most can’t read or understand the language, and the people – though very helpful for the most part –often stare at foreigners like an unfamiliar curiosity. Coming from a country like Canada, the United States, or Britain where there are so many people of different races with different faces, rarely is a second glance given to someone due to their skin color being different. This is one of the first things you come to understand coming from another country, Korea is for the most part a mono-culture, inhabited by a single race with close ties to the surrounding countries, such as China and Japan. In larger cities such as Seoul and Busan, where there is a much larger foreign population, most Koreans are used to seeing foreigners. In smaller communities, however, foreigners are more of an oddity – though this is changing gradually. Some call this "the celebrity effect".
European countries speak great English, Asian countries are in the middle, and everyone else lags English will maintain and grow its dominance, moving from “a marker of the elite” in years past to “a basic skill needed for the entire workforce, in the same way that literacy has been transformed in the last two centuries from an elite privilege into a basic requirement for informed citizenship.”
English language turns into big business asset as the international language of business, the teaching of English has turned into an industry worth 1.5 billion a year.
Great Morning That National Bank seller is out as of this morning!!!!!
Let's go Titan
TLTFF is the real deal these new posters are making it look like a pump and dump but I am long and TLTFF will prevail.
I do not know where the posters on TLTFF came from, I have been in TLTFF for a long time and I am long on both TITXF and TLTFF.
TLTFF has had many write ups and is starting to look good, maybe TLTFF has been hijacked by these new posters or maybe they are real investors?
I will have another soon but I am not finished my DD. Will keep you posted though.
I am holding long and strong with you.
Welcome to the board everyone GLTA
Loyalist Settles All Payments For King George Schools
Moving Forward And Upward
Loyalist settles all payments for King George schools
Loyalist Group Ltd (C:LOY)
Shares Issued 148,814,592
Last Close 3/19/2014 $0.68
Friday March 21 2014 - News Release
Mr. Andrew Ryu reports
LOYALIST SATISFIES OUTSTANDING AMOUNTS OWING IN RESPECT OF KGIC ACQUISITION
Loyalist Group Ltd. has satisfied all undisputed amounts owing under the promissory note given by it in connection with the acquisition of King George International College (KGIC), an accredited and licensed English-as-a-second-language (ESL) school, and King George International Business College (KGIBC), a registered career college in Toronto, Vancouver and Victoria, which was previously announced on Sept. 18, 2013. KGIC and KGIBC have a total of eight campuses in Halifax, Toronto, Vancouver and Victoria.
"The company continues to work through the final stages of the integration of KGIC and KGIBC with the other brands under the Loyalist label, and we are very pleased with the co-operative manner in which this integration is being accomplished," stated Andrew Ryu, chief executive officer of Loyalist.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd.
Loyalist Settles All Payments For King George Schools
Moving Forward And Upward
Loyalist settles all payments for King George schools
Loyalist Group Ltd (C:LOY)
Shares Issued 148,814,592
Last Close 3/19/2014 $0.68
Friday March 21 2014 - News Release
Mr. Andrew Ryu reports
LOYALIST SATISFIES OUTSTANDING AMOUNTS OWING IN RESPECT OF KGIC ACQUISITION
Loyalist Group Ltd. has satisfied all undisputed amounts owing under the promissory note given by it in connection with the acquisition of King George International College (KGIC), an accredited and licensed English-as-a-second-language (ESL) school, and King George International Business College (KGIBC), a registered career college in Toronto, Vancouver and Victoria, which was previously announced on Sept. 18, 2013. KGIC and KGIBC have a total of eight campuses in Halifax, Toronto, Vancouver and Victoria.
"The company continues to work through the final stages of the integration of KGIC and KGIBC with the other brands under the Loyalist label, and we are very pleased with the co-operative manner in which this integration is being accomplished," stated Andrew Ryu, chief executive officer of Loyalist.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd.
Dr. Sarah Eaton, an educational leader, researcher, author, and professional speaker, wrote an article about the differences between public and private ESL institutions, taking specific focus on Loyalist to highlight some inherent differences.
Here is an excerpt:
"But there’s a new form of “public” education on the block and it is not to be ignored. Educational companies that are publicly traded on the stock market are drastically different from private companies. Public companies are obliged to share financial information with shareholders and investors. The accountability to the people who choose to put their dollars into the company is significant. Shareholders can ask questions — and demand answers. If their students are not happy or successful, they’ll leave. Sales will drop and they’ll close their doors. Their very existence depends on their students’ success... But public companies put it all out there for anyone to look at, scrutinize and ultimately judge. That’s a good thing. When it comes to ESL, it’s more transparent than what we see in public institutions. The very nature of accountability and reporting in education in Canada is changing… It’s strange, but true that when it comes to ESL, publicly traded companies like Loyalist Group Ltd may turn out to be more transparent, more accountable and more responsive to questioning from outsiders than some “public” institutions."
Here is a link to the full article:
http://drsaraheaton.wordpress.com/2014/02/18/a-new-kind-of-loyalist-public-esl-education-takes-on-a-whole-new-twist-in-canada/
Dr. Sarah Eaton, an educational leader, researcher, author, and professional speaker, wrote an article about the differences between public and private ESL institutions, taking specific focus on Loyalist to highlight some inherent differences.
Here is an excerpt:
"But there’s a new form of “public” education on the block and it is not to be ignored. Educational companies that are publicly traded on the stock market are drastically different from private companies. Public companies are obliged to share financial information with shareholders and investors. The accountability to the people who choose to put their dollars into the company is significant. Shareholders can ask questions — and demand answers. If their students are not happy or successful, they’ll leave. Sales will drop and they’ll close their doors. Their very existence depends on their students’ success... But public companies put it all out there for anyone to look at, scrutinize and ultimately judge. That’s a good thing. When it comes to ESL, it’s more transparent than what we see in public institutions. The very nature of accountability and reporting in education in Canada is changing… It’s strange, but true that when it comes to ESL, publicly traded companies like Loyalist Group Ltd may turn out to be more transparent, more accountable and more responsive to questioning from outsiders than some “public” institutions."
Here is a link to the full article:
http://drsaraheaton.wordpress.com/2014/02/18/a-new-kind-of-loyalist-public-esl-education-takes-on-a-whole-new-twist-in-canada/
Yes the 52 low is .15 cents I was meaning this year in 2014
The CEO has been on a road show since Jan 2014 he was at the Cantech Letter Conference in Toronto, Canada and the Alpha North tour from the Bahamas including the USA Cambridge House Live and much much more. The company had free trading warrants mature that has pasted, so now I am excepting news/updates on what has been achieved and what is coming out over the last quarter I feel there is something worth movement up from where we are now.
I have seen numerous letter writers coming forward and the company is advancing with revenue models too. I have a good feeling that we might have a new 52 week high coming as I feel we found the 52 week low just my humble opinion here. Do your own dd before investing your hard earned money or just watch to see if I am correct in my opinion. GLTA